Targeted drug trial for advanced cancers halted early
NCT ID NCT06005974
Summary
This study tested an oral drug called REC-4881 in adults with advanced solid tumors that had spread and carried specific gene changes (AXIN1 or APC). The goal was to see if the drug was safe and could help control the cancer in people who had already tried standard treatments. The trial was terminated early and enrolled only 18 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
American Oncology Partners of Maryland, PA
Bethesda, Maryland, 20817, United States
-
Avera Cancer Institute
Sioux Falls, South Dakota, 57105, United States
-
Cancer Specialists of North Florida
Fleming Island, Florida, 32003, United States
-
Eastern Connecticut Hematology & Oncology Associates
Norwich, Connecticut, 06360, United States
-
Hunterdon Hematology Oncology
Hillsborough, New Jersey, 08844, United States
-
Mary Crowley Cancer Research Centers
Dallas, Texas, 75231, United States
-
Medical Oncology Hematology Consultants
Newark, Delaware, 19713, United States
-
Mission Cancer And Blood
Des Moines, Iowa, 50314, United States
-
Rocky Mountain Cancer Centers
Denver, Colorado, 80218, United States
-
Saint Luke's Hospital
Kansas City, Missouri, 64111, United States
-
Sansum Clinic
Santa Barbara, California, 93105, United States
-
Sharp Memorial Hospital
San Diego, California, 92123, United States
-
Virginia Cancer Specialists
Fairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.